Suliman Khan
*
Rabeea Siddique
The final, formatted version of the article will be published soon.
EDITORIAL article
Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1468397
This article is part of the Research Topic Molecular Mechanisms and Immunotherapeutic Targets in Nanomedicine-based Cancer Therapy View all 6 articles
Molecular Mechanisms and Immunotherapeutic Targets in Nanomedicine-based Cancer Therapy
Provisionally accepted- Medical Research Center, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Zhengzhou, China
Keywords: nanomedcine, immunotherapeutic, Cancer, Immune responce, nanomaterial
Received: 22 Jul 2024; Accepted: 05 Sep 2024.
Copyright: © 2024 Khan and Siddique. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Suliman Khan, Medical Research Center, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.